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Abstract
Background: Oxidative stress is involved in the initiation and progression of atherosclerosis, and hyperglycemia is
known to increase oxidative stress, which injures the endothelium and accelerates atherosclerosis. To clarify the
relation between oxidative stress, diabetes mellitus (DM), and acute myocardial infarction (AMI), we evaluated and
compared time-specific oxidative stress after AMI in patients with and without DM by simple measurement of
derivatives of reactive oxygen metabolites (d-ROMs) levels as indices of reactive oxygen species production.
Methods: Sixty-eight AMI patients were enrolled (34 non-DM patients and 34 DM patients). Using the FRAS4 free radical
analytical system, we measured d-ROMs levels in each patient at two time points: 1 and 2 weeks after AMI onset.
Results: d-ROM levels decreased significantly between week 1 and week 2 (from 475.4 ± 119.4 U.CARR to 367.7 ± 87.9
U.CARR, p < 0.001) in the non-DM patients but did not change in the DM patients (from 463.1 ± 109.3 U.CARR to 461.7 ±
126.8 U.CARR, p= 0.819). Moreover, significant correlation was found in the total patient group between d-ROMs levels at
1 week and N-terminal prohormone of brain natriuretic peptide (r = 0.376, p = 0.041) and between d-ROM levels at
2 weeks and 2-hour oral glucose tolerance test glucose levels (r = 0.434, p < 0.001).
Conclusions: Exposure to oxidative stress is greater in AMI patients with DM than AMI patients without DM. Our study
results suggest that it is the continuous hyperglycemia that increases oxidative stress in these patients, causing
endothelial dysfunction and accelerating atherosclerosis. However, long-term follow up study is needed to assess
whether the increased oxidative stress affects patient outcomes.
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Background
Oxidative stress, which is implicated in various disorders,
especially lifestyle-related diseases such as diabetes mellitus
(DM), is involved in the initiation and progression of ath-
erosclerosis [1–3]. Biomarkers of oxidative stress, such as
serum malondialdehyde measured as thiobarbituric acid-
reactive substances, oxidized low-density lipoprotein, oxida-
tive DNA damage byproduct 8-hydroxydeoxyguanosine,
and urinary 8-iso-prostaglandin-F2α, are generally mea-
sured in research laboratories [4–7]. Indices of antioxidant
potential, especially intracellular levels of superoxide
dismutase and glutathione peroxidase, are also measured
[8, 9]. However, the assay methods are complex and not
suitable for large-scale analysis. Simpler means of detecting
reactive oxygen species (ROS) by assay of derivatives of
reactive oxygen metabolites (d-ROMs) and biological anti-
oxidant potential have been developed, and reports of these
methods and studies based on these methods have been
increasing [10–19].
DM is a major risk factor for cardiovascular disease.
Continuous hyperglycemia increases advanced glycation
end products (AGEs) and induces ROS production [20].
ROS plays a pivotal role in the development of the
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microvascular and cardiovascular complications of DM.
The increased ROS in patients with type 2 DM and
metabolic syndrome is a consequence of metabolic ab-
normalities, including hyperglycemia, insulin resistance,
hyperinsulinemia, and dyslipidemia [21], each of which
contributes to mitochondrial superoxide overproduction
in endothelial cells of large and small vessels as well as
the myocardium [22]. The atherosclerosis is accelerated
and may induce acute coronary syndrome.
Thus, we are interested in the relations between oxida-
tive stress, DM, and acute myocardial infarction (AMI),
we evaluated and compared time-specific oxidative stress
after AMI in patients with and without DM by simple




The study involved 68 consecutive patients who had
suffered an ST-elevated AMI, admitted to the coronary
care unit of Nihon University Itabashi Hospital between
April 2010 and March 2011, and underwent successful
primary percutaneous coronary intervention (PCI).
Thirty-four had type 2 DM (DM group) and 34 did not
(non-DM group). Patients with severe MI; those recover-
ing from cardiopulmonary arrest or heart failure; and
those with cardiomyopathy, severe valvular disease, atrial
fibrillation, chronic kidney disease requiring hemodialysis,
type 1 DM, type 2 DM requiring insulin or glucagon-like
peptide-1 receptor agonists treatment, collagen disease, or
malignant tumor were excluded from the study. Medica-
tions patients had been taking were not changed, and
anti-diabetic agents were not given during the study
period. We also collected d-ROM values in stable coron-
ary artery disease (CAD) patients without DM (n = 40)
and with DM (n = 28) as reference value, they had under-
gone coronary stenting for stable CAD except acute cor-
onary syndrome more than 8 months before data
collection.
The study was approved by the ethics committee of
Nihon University Itabashi Hospital, and written in-
formed consent was provided by each patient for
participation.
Clinical evaluation and laboratory measurements
Patients’ clinical characteristics, including age, sex,
body mass index, smoking history, and history of
hypertension and dyslipidemia were recorded, and
blood samples were drawn 1 week after AMI onset
for measurement of hemoglobin A1c (HbA1c), fasting
glucose, total cholesterol, low-density lipoprotein-
cholesterol, high-density lipoprotein-cholesterol, creat-
ine phosphokinase (CPK), estimated glomerular filtra-
tion rate (eGFR), high-sensitivity C-reactive protein
(hs-CRP) and N-terminal prohormone of brain natri-
uretic peptide (NT-proBNP). Insulin resistance was
evaluated by means of homeostasis model assessment
of insulin resistance (HOMA-IR), and an oral glucose
tolerance test (OGTT) was given to evaluate glucose
clearance.
Assay of oxidative stress
We quantified hydrogen peroxide levels by measuring d-
ROMs using the FRAS4 Free Radical Analytical System
(H&D srl, Parma, Italy). Hydrogen peroxides are con-
verted into radicals that oxidize N, N-diethyl-para-phenyl-
enediamine and can be detected spectrophotometrically
with the use of an all-purpose automatic analyzer. The
d-ROM levels are expressed in arbitrary units called
Carratelli units (U.CARR) [10]. The normal reference level
of d-ROMs is 250 to 300 U.CARR [23, 24]. We measured
d-ROMs at 2 time points, 1 week and 2 weeks after AMI
onset, to avoid the possible influence of AMI.
Statistical analysis
Continuous variables are expressed as mean ± SD values,
and categorical variables are presented as numbers and
percentages. Between-group differences were analyzed
by one-way ANOVA with Tukey post-hoc honest signifi-
cant difference test or by chi-square test, as appropriate.
Differences between 1-week and 2-week values were
analyzed by paired t-test, Wilcoxon signed-rank test, or
unpaired t-test, as appropriate. Association between d-
ROM levels and clinical variables was tested by linear re-
gression analysis, and factors predictive of no or little
change in the d-ROM level between 1 and 2 weeks after
AMI were identified by multiple logistic regression ana-
lysis. Statistical analyses were performed with JMP ver. 9
(SAS Institute, Cary, NC, USA). A p value of 0.05 was
considered significant.
Results
Patients’ clinical characteristics and laboratory values
Clinical characteristics of the study patients are shown in
Table 1. Only HbA1c, fasting plasma glucose, 2-h OGTT
glucose, HOMA-IR, eGFR, and the use of nitrate differed
significantly between the two patient groups. Additional
file 1 shows clinical characteristics of reference patients.
Changes in oxidative stress
Shown in Fig. 1, the d-ROMs level 1 week after AMI did
not differ significantly between the DM group and the
non-DM group (463.1 ± 109.3 U.CARR vs. 475.4 ± 119.4
U.CARR, respectively, p = 0.382). At 2 weeks after AMI,
the d-ROMs level had decreased significantly in the
non-DM group (from 475.4 ± 119.4 U.CARR to 367.7 ±
87.9 U.CARR, p < 0.001) but remained unchanged in the
DM group (from 463.1 ± 109.3 U.CARR to 461.7 ± 126.8
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U.CARR, p = 0.819). Reference d-ROM values are shown
in Additional file 2, the value in stable CAD patients
without DM was 341.7 ± 101.7 U.CARR, and the value
in those with DM was 377 ± 128.3 U.CARR. There was
no signifincat difference between these values.
Major determinant of changes in oxidative stress
In the total patient group, significant positive correlation
was found between d-ROMs levels 1 week after AMI
and NT-proBNP levels (r = 0.376, p = 0.041) (Fig. 2, left
panel) and between d-ROMs levels at 2 weeks and 2-h
OGTT glucose levels (r = 0.434, p < 0.001) (Fig. 2, right
panel). There was no relation between the d-ROMs level
and age, sex, BMI, glucose profiles except 2-h OGTT
glucose level, renal function, CPK, lipids, or use of the
various medications. Multivariate logistic regression
analysis showed the presence of DM to be a significant
predictor of little or no change in the d-ROMs level by
2 weeks after AMI (Table 2), after adjustment for signifi-
cant factors identified by univariate analysis (odds ratio:
3.33, 95 % confidence interval: 1.15–10.48) (Table 2).
Discussion
Oxidative stress is implicated in various disorders and
pathogeneses. Many studies have shown its involvement
in the pathogeneses of lifestyle-related diseases. Previous
clinical studies have made use of markers of ROS, such
as 8-hydroxydeoxyguanosine and 8-iso-prostaglandin-
F2α. However, it is difficult to measure these markers at
health checkup facilities. Furthermore, superoxide
dismutase, which can serve as an index of antioxidant
potential, is also difficult to measure, even at research fa-
cilities. In this study, we used a simple assay method to
examine the course of oxidative stress between 1 week
and 2 weeks after AMI in patients with DM. This is the
first study to observe time-specific change in oxidative
stress in the early stage after AMI and to examine the
difference in exposure to oxidative stress between pa-
tients with DM and those without DM.
Recent studies have shown the usefulness d-ROMs
assay for evaluating oxidative stress [13–15, 17], and in
such evaluation, Trotti et al. found no statistically signifi-
cant difference between male and female Europeans
[11], whereas Fukui et al. found the mean d-ROMs level
Table 1 Clinical characteristics of study patients upon
enrollmenta, per study group
non-DM DM p valueb
n = 34 n = 34
Age (years) 62.1 ± 9.6 61.4 ± 9.9 0.739
Sex, male (%) 32 (94.1) 29 (85.3) 0.259
BMI 24.7 ± 2.5 25.3 ± 2.6 0.293
Risk factors
Hypertension, n (%) 28 (82.4) 29 (85.3) 0.742
Dyslipidemia, n (%) 26 (76.5) 26 (76.5) 1.000
Smoking, n (%) 19 (55.9) 23 (67.6) 0.318
Biochemical markers
HbA1c (%) 5.6 ± 0.3 6.6 ± 0.5 <0.001
Fasting plasma glucose
(mg/dL)
97.5 ± 7.4 114.6 ± 18.6 <0.001
2 h OGTT plasma glucose
(mg/dL)
119.8 ± 13.0 172.7 ± 33.7 <0.001
HOMA-IR 1.53 ± 0.81 2.73 ± 1.89 <0.001
eGFR (mL/min/1.73 m2) 63.2 ± 16.0 71.7 ± 16.5 0.035
CPK (maximum) (U/L) 3532.2 ± 3898.3 2360.6 ± 2181.8 0.247
hs-CRP (mg/dL) 0.654 ± 0.695 0.828 ± 0.712 0.311
Total cholesterol (mg/dL) 199.9 ± 35.3 196.0 ± 57.4 0.954
Triglyceride (mg/dL) 95.0 ± 55.2 127.6 ± 77.8 0.277
HDL cholesterol (mg/dL) 46.6 ± 12.3 45.8 ± 10.0 0.825
LDL cholesterol (mg/dL) 134.3 ± 29.5 116.7 ± 37.0 0.752
NT-proBNP (pg/mL) 804.8 ± 1057.8 645.1 ± 915.0 0.578
Medications
Ca channel blocker, n (%) 9 (26.5) 6 (17.6) 0.470
Beta blocker, n (%) 19 (55.9) 18 (52.9) 0.924
ACE-I/ARB, n (%) 22 (64.7) 25 (73.5) 0.504
Nitrate, n (%) 30 (88.2) 18 (52.9) 0.004
Statin, n (%) 24 (70.6) 23 (67.6) 0.853
aAt 1 week after AMI onset
Data are expressed as mean ± SD or number (%). bobtained by ANOVA or chi-
square test. HbA1c, fasting plasma glucose, 2 h OGTT plasma glucose, HOMA-
IR and eGFR levels were significantly higher and the use of nitrate was signifin-
catly lower in DM patients group. DM diabetes mellitus, BMI body mass index,
HbA1c hemoglobin A1c, OGTT oral glucose tolerance test, HOMA-IR homeo-
static model assessment-insulin resistance, eGFR estimated glomerular filtration
rate, CPK creatine phosphokinase, hs-CRP high-sensitivity C-reactive protein, HDL
high density lipoprotein, LDL low density lipoprotein, NT-proBNP N-terminal
prohormone of brain natriuretic peptide, ACE-I angiotensin converting enzyme
inhibitor, ARB, angiotensin receptor blocker
Fig. 1 Change in the serum d-ROMs levels after AMI in patients with
and without DM. d-ROMs, derivatives of reactive oxygen metabolites;
AMI, acute myocardial infarction; DM, diabetes mellitus
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in female Japanese to be significantly higher than that in
male Japanese [25]. Moreover positive correlation
between levels of hs-CRP and d-ROMs has been re-
ported [14, 15, 17]. Nevertheless, we found that most
clinical characteristics, including sex and hs-CRP, are
not factors that significantly influence d-ROMs in
patients with AMI. However, we did find that the NT-
proBNP level was a significant predictor of the d-
ROMs level at 1 week after AMI. This is consistent
with the previously reported correlation between BNP
and post-MI remodeling [26–28]. Furthermore, DM
and hyperglycemia were identified as predictors of
non-suppression of ROS production after AMI. Thus,
it appears that the d-ROMs level at 1 week is influ-
enced by the effect of MI on the heart itself, whereas
the d-ROMs level at 2 weeks is the result of the con-
tinuous DM-induced hyperglycemia.
Continuous hyperglycemia increases production of
AGEs and high levels of AGEs have been found in the
cardiac tissue of diabetic patients [29]. AGEs induce oxi-
dative stress and activate the protein kinase C/diacyl-
glycerol signaling pathway, which is one of the
mechanisms by which hyperglycemia exerts adverse car-
diovascular effects. In addition, AGEs activate ROS pro-
duction in mitochondria [20]. Increases in ROS cause
cardiac dysfunction by directly damaging proteins and
DNA and by inducing apoptosis [30]. We have reported
a study in which we treated patients with alpha-
glucosidase inhibitor (α-GI) from 1 week to 2 weeks after
AMI [31]. In that study, we found that the d-ROMs level
in patients treated with α-GI tended to decrease and that
endothelial function improved. Thus, oxidative stress plays
a pivotal role in the development of the microvascular and
cardiovascular complications of DM.
There are some limitations to the present study. First,
this was an association study using a case–control
design and not randomized, however, the patient charac-
teristics were well matched between groups (Table 1).
Second, sample size was small and this was a single-
center study. Therefore, we are not able to apply our
result to the general population. Third, although we
showed reference d-ROM values in stable CAD patients
(Additional file 2: Table S1), this was a very short-term
follow-up study, and because we did not record d-ROMs
levels before AMI or primary PCI and after PCI or more
than 2 weeks after AMI, any difference in d-ROMs levels
after primary PCI and any progressive change in
Table 2 Factors tested as predictors of lack of change in the d-
ROMs level 2 weeks after AMI
Univariate analysis Multivariate analysis
Factor OR (95 % CI) p value OR (95 % CI) p value
Age 1.01 (0.95–1.07) 0.677
Sex 1.50 (0.31–10.87) 0.629
BMI 1.09 (0.89–1.35) 0.396




2 h OGTT glucose
level
1.02 (1.00–1.03) 0.032 1.02 (1.00–1.04) 0.098
HOMA-IR 1.10 (0.79–1.51) 0.570
eGFR 1.00 (0.98–1.04) 0.675
CPK (maximum) 1.00 (1.00–1.00) 0.354
LDL cholesterol 0.99 (0.97–1.01) 0.424
hs-CRP 1.05 (0.48–2.13) 0.904




Beta blocker 3.35 (0.84–17.03) 0.105
ACE-I/ARB 0.38 (0.02–3.38) 0.428
Nitrate 0.20 (0.05–0.83) 0.028 0.36 (0.07–1.89) 0.216
Statin 0.39 (0.09–1.60) 0.180
Multivariate logistic regression analysis showed the presence of diabetes
mellitus was a significant predictor of no change in the d-ROMs level by 2
weeks after AMI. d-ROMs derivatives of reactive oxygen metabolites, AMI acute
myocardial infarction, OR odds ratio, CI confidence interval, BMI body mass
index, OGTT oral glucose tolerance test, HOMA-IR homeostatic model
assessment-insulin resistance, eGFR estimated glomerular filtration rate, CPK
creatine phosphokinase, LDL low density lipoprotein, hs-CRP high-sensitivity C-
reactive protein, NT-proBNP N-terminal prohormone of brain natriuretic pep-
tide, ACE-I angiotensin converting enzyme inhibitor, ARB
angiotensin receptor blocker
Fig. 2 Correlation between d-ROMs levels and NT-proBNP levels at 1 week after AMI (left) and between d-ROMs levels at 2 weeks after AMI and
glucose levels at 2 h after OGTT (right). d-ROMs, derivatives of reactive oxygen metabolites; AMI, acute myocardial infarction; NT-proBNP, N-
terminal prohormone of brain natriuretic peptide; OGTT, oral glucose tolerance test
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oxidative stress after AMI in patients with DM remain
unknown. Fourth, we excluded patients with heart fail-
ure resulting from severe MI, first, because it has been
reported that DM can lead to heart failure after MI, and
second, because oxidative stress may be high in patients
with heart failure [32, 33].
Conclusions
Our study showed that patients with DM are subject to
clinically significant oxidative stress during the first
2 weeks after AMI. Although long-term changes in
oxidative stress after AMI in patients with DM remain
unknown, results of this short-term follow-up study
imply that continuous hyperglycemia drives oxidative
stress after AMI, leading to endothelial dysfunction, and
progression of atherosclerosis.
Additional files
Additional file 1: Clinical characteristics of reference patients with
stable CAD, per group. (DOCX 21 kb)
Additional file 2: d-ROM levels in stable CAD patient with DM and
without DM. These data were collected from stable CAD patients with
DM and without DM, who had undergone coronary stenting for stable
CAD except ACS more than 8 months before data collection. Values are
expressed as mean ± SD, and boxes show median and interquartile
ranges between the 25th and the 75th percentiles. d-ROM, derivatives of
reactive oxygen metabolites; CAD, coronary artery disease; DM, diabetes
mellitus; ACS, acute coronary syndrome. (DOCX 385 kb)
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